BSE Live
Apr 15, 16:01Prev. Close
53.08
Open Price
52.82
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of OXYGENTA PHARMACEUTICAL (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -5.99 | -4.20 | -1.63 | -0.23 | -0.14 | |
| Diluted EPS (Rs.) | -5.99 | -4.20 | -1.63 | -0.23 | -0.14 | |
| Cash EPS (Rs.) | -3.51 | -3.36 | -1.64 | -0.23 | -0.15 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | -15.75 | -9.09 | -4.89 | -3.25 | -3.02 | |
| Book Value [InclRevalReserve]/Share (Rs.) | -15.75 | -9.09 | -4.89 | -3.25 | -3.02 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 6.12 | 2.42 | 0.00 | 0.00 | 0.00 | |
| PBDIT/Share (Rs.) | -4.03 | -3.17 | -1.42 | -0.23 | -0.15 | |
| PBIT/Share (Rs.) | -6.52 | -4.01 | -1.42 | -0.23 | -0.15 | |
| PBT/Share (Rs.) | -6.72 | -4.02 | -1.42 | -0.23 | -0.15 | |
| Net Profit/Share (Rs.) | -5.99 | -4.20 | -1.64 | -0.23 | -0.15 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -65.88 | -130.74 | 0.00 | 0.00 | 0.00 | |
| PBIT Margin (%) | -106.48 | -165.56 | 0.00 | 0.00 | 0.00 | |
| PBT Margin (%) | -109.80 | -165.99 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin (%) | -97.95 | -173.61 | 0.00 | 0.00 | 0.00 | |
| Return on Networth / Equity (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Return on Capital Employed (%) | -276.04 | -67.72 | -23.31 | -5.73 | -3.62 | |
| Return on Assets (%) | -33.80 | -23.57 | -9.95 | -1.73 | -1.10 | |
| Total Debt/Equity (X) | -0.89 | -1.12 | -1.63 | -1.31 | -1.34 | |
| Asset Turnover Ratio (%) | 34.50 | 13.57 | 0.00 | 0.00 | 0.00 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.35 | 0.14 | 0.12 | 0.07 | 0.07 | |
| Quick Ratio (X) | 0.31 | 0.13 | 0.12 | 0.07 | 0.07 | |
| Inventory Turnover Ratio (X) | 11.86 | 78.87 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 22.82 | 17.71 | 14.86 | 12.47 | 12.56 | |
| EV/Net Operating Revenue (X) | 3.66 | 7.17 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | -5.55 | -5.48 | -10.26 | -52.85 | -83.44 | |
| MarketCap/Net Operating Revenue (X) | 1.37 | 2.97 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | -0.53 | -0.79 | -1.47 | -2.45 | -2.73 | |
| Price/Net Operating Revenue | 1.37 | 2.97 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | -0.71 | -0.58 | -0.23 | -0.03 | -0.02 |
09.02.2026
OXYGENTA PHARMA Standalone December 2025 Net Sales at Rs 33.93 crore, up 2.18% Y-o-Y
12.11.2025
OXYGENTA PHARMA Standalone September 2025 Net Sales at Rs 14.30 crore, up 2.12% Y-o-Y
11.06.2025
OXYGENTA PHARMA Standalone March 2025 Net Sales at Rs 49.47 crore, up 368.77% Y-o-Y
25.11.2024
OXYGENTA PHARMA Standalone September 2024 Net Sales at Rs 14.01 crore, up 7.11% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth